Security
Kura Oncology, Inc. Common Stock · KURO
KUROOTCCommon stockHistorical · closed Aug 24, 2015CIK 1422143Updated Nov 15, 2026
Name history
ZETA ACQUISITION CORP III · through Mar 10, 2015
Current security for this SEC filerKURA · NASDAQ
KURO price & chart
Historical security
This listing closed Aug 24, 2015. Live provider charts are shown only for current listings.
Current security: KURA
About the company
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.
In the news
No coverage from other publishers is available.
Recent filings
S-3ASR filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 649,381,000Source | 478,837,000Source | 587,791,000Source | 682,425,000Source | 515,116,000Source | 652,551,000Source | 743,764,000Source | 553,908,000Source | 738,363,000Source | 760,159,000Source | 448,935,000Source | 456,306,000Source |
| Property, Plant and Equipment, NetUSD | 7,397,000Source | 1,315,000Source | 7,586,000Source | 3,912,000Source | 1,523,000Source | 7,613,000Source | 2,348,000Source | 1,709,000Source | 7,855,000Source | 1,682,000Source | 1,859,000Source | 2,540,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 95,287,000Source | 49,480,000Source | 70,242,000Source | 81,948,000Source | 45,183,000Source | 39,083,000Source | 51,269,000Source | 41,506,000Source | 149,099,000Source | 224,462,000Source | 37,318,000Source | 51,802,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 35,936,000Source | — | 9,446,000Source | 4,574,000Source | — | 9,348,000Source | 48,746,000Source | — | 8,804,000Source | — | — | — |
| Inventory, NetUSD | — | — | 2,485,000Source | — | — | 843,000Source | — | — | 413,000Source | — | — | — |
| Assets, CurrentUSD | 620,663,000Source | 463,189,000Source | 559,439,000Source | 660,075,000Source | 499,768,000Source | 623,782,000Source | 724,198,000Source | 537,835,000Source | 708,663,000Source | 744,829,000Source | 432,481,000Source | 446,426,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 35,062,000Source | 7,892,000Source | 28,483,000Source | 24,773,000Source | 8,249,000Source | 32,768,000Source | 17,261,000Source | 10,713,000Source | 32,206,000Source | 17,434,000Source | 8,524,000Source | 8,441,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,539,000Source | 6,100,000Source | 7,038,000Source | 7,864,000Source | 6,400,000Source | 7,166,000Source | 8,139,000Source | 6,698,000Source | 7,302,000Source | 5,803,000Source | 6,993,000Source | 3,842,000Source |
| Other Assets, NoncurrentUSD | 13,782,000Source | 8,233,000Source | 13,728,000Source | 10,574,000Source | 7,425,000Source | 13,990,000Source | 9,079,000Source | 7,666,000Source | 14,543,000Source | 7,845,000Source | 7,602,000Source | 3,288,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 406,839,000Source | 55,066,000Source | 539,360,000Source | 376,939,000Source | 49,046,000Source | 544,668,000Source | 379,358,000Source | 48,824,000Source | 564,228,000Source | 346,519,000Source | 51,662,000Source | 36,028,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 9,000Source | 8,000Source | 9,000Source | 9,000Source | 8,000Source | 9,000Source | 8,000Source | 8,000Source | 9,000Source | 8,000Source | 7,000Source | 7,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,093,089,000Source | -876,205,000Source | -1,315,748,000Source | -1,018,973,000Source | -821,801,000Source | -1,247,421,000Source | -952,851,000Source | -770,964,000Source | -1,174,088,000Source | -895,422,000Source | -721,439,000Source | -568,808,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | 1,116,000Source | — | 711,000Source | -463,000Source | — | 974,000Source | -816,000Source | 1,024,000Source | 764,000Source | -1,271,000Source | -8,032,000Source |
| Stockholders' Equity Attributable to ParentUSD | 242,542,000Source | 423,771,000Source | 48,431,000Source | 305,486,000Source | 466,070,000Source | 107,883,000Source | 364,406,000Source | 505,084,000Source | 174,135,000Source | 413,640,000Source | 397,273,000Source | 420,278,000Source |
| Additional Paid in Capital, Common StockUSD | 1,334,704,000Source | 1,298,852,000Source | 1,365,383,000Source | 1,323,739,000Source | 1,288,326,000Source | 1,355,675,000Source | 1,316,275,000Source | 1,276,856,000Source | 1,347,190,000Source | 1,308,290,000Source | 1,119,976,000Source | 997,111,000Source |
| Liabilities and EquityUSD | 649,381,000Source | 478,837,000Source | 587,791,000Source | 682,425,000Source | 515,116,000Source | 652,551,000Source | 743,764,000Source | 553,908,000Source | 738,363,000Source | 760,159,000Source | 448,935,000Source | 456,306,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 121,304,000Source | 40,372,000Source | 118,193,000Source | 107,174,000Source | 33,451,000Source | 101,496,000Source | 89,766,000Source | 32,266,000Source | 116,974,000Source | 78,712,000Source | 35,263,000Source | 24,057,000Source |
| Operating Lease, Liability, CurrentUSD | 1,429,000Source | 1,691,000Source | 1,291,000Source | 1,696,000Source | 1,467,000Source | 1,283,000Source | 1,905,000Source | 1,363,000Source | 1,277,000Source | 1,881,000Source | 1,506,000Source | 2,318,000Source |
| Accounts Payable, CurrentUSD | 4,671,000Source | 3,006,000Source | 2,392,000Source | 1,704,000Source | 2,064,000Source | 7,043,000Source | 4,610,000Source | 7,529,000Source | 5,017,000Source | 1,469,000Source | 2,300,000Source | 1,533,000Source |
| Operating Lease, Liability, NoncurrentUSD | 8,364,000Source | 5,466,000Source | 13,374,000Source | 8,156,000Source | 5,843,000Source | 13,241,000Source | 7,878,000Source | 6,231,000Source | 9,469,000Source | 5,190,000Source | 6,362,000Source | 2,548,000Source |
| Other Liabilities, NoncurrentUSD | 2,981,000Source | 1,471,000Source | 3,616,000Source | 2,595,000Source | 1,176,000Source | 3,437,000Source | 2,139,000Source | 951,000Source | 3,165,000Source | 1,795,000Source | 705,000Source | 265,000Source |
| Additional Financial Items | ||||||||||||
| Long-term Debt, Current MaturitiesUSD | 4,337,000Source | 1,715,000Source | 4,217,000Source | 3,112,000Source | 847,000Source | — | 1,921,000Source | — | 0Source | 2,607,000Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 5,336,000Source | 7,757,000Source | 5,573,000Source | 6,509,000Source | 8,576,000Source | 9,749,000Source | 7,650,000Source | 9,376,000Source | 9,711,000Source | 6,916,000Source | 9,332,000Source | 9,158,000Source |
| AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax | —Source | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 8,416,000Source | 7,842,000Source | 37,108,000Source | 33,897,000Source | 28,082,000Source | 26,318,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 544,000Source | 46,686,000Source | 6,744,000Source | — | — | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 430,000Source | — | 413,000Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 2,026,000Source | 3,141,000Source | 4,499,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -85,854,000Source | -71,927,000Source | -64,058,000Source | 134,317,000Source | -124,824,000Source | -110,062,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -24,231,000Source | -101,409,000Source | -13,098,000Source | -101,590,000Source | 15,557,000Source | 32,627,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 128,000Source | 292,000Source | 6,638,000Source | 472,000Source | 168,000Source | 626,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 69,000Source | 143,000Source | 1,793,000Source | 154,417,000Source | 94,783,000Source | 38,565,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -110,016,000Source | -173,193,000Source | -75,363,000Source | 187,144,000Source | -14,484,000Source | -38,870,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 95,287,000Source | 49,480,000Source | 70,242,000Source | 81,948,000Source | 39,083,000Source | 51,269,000Source | 149,099,000Source | 224,462,000Source | 37,318,000Source | 52,012,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 998,000Source | 1,096,000Source | 1,064,000Source | 73,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 2,308,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 10,965,000Source | 8,324,000Source | 8,209,000Source | 6,949,000Source | 8,416,000Source | 7,842,000Source | 37,108,000Source | — | — | — |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 106,000Source | 133,000Source | 515,000Source | 523,000Source | 477,000Source | — |
| DepreciationUSD | — | — | — | — | — | — | 355,000Source | 241,000Source | 1,032,000Source | 848,000Source | 849,000Source | 759,000Source |
| General and Administrative ExpenseUSD | — | — | 32,839,000Source | 18,179,000Source | — | 25,169,000Source | — | 22,835,000Source | — | 77,111,000Source | 50,569,000Source | 47,053,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 5,000Source | — | 8,000Source | 226,000Source | 297,000Source | 2,018,000Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 393,000Source | 412,000Source | 345,000Source | 391,000Source | 336,000Source | 382,000Source | 1,512,000Source | 1,619,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -74,116,000Source | -54,404,000Source | -68,327,000Source | -66,122,000Source | -73,333,000Source | -57,429,000Source | -278,666,000Source | -173,983,000Source | -152,631,000Source | -135,840,000Source |
| Nonoperating Income (Expense)USD | — | — | 5,881,000Source | 5,480,000Source | 4,688,000Source | 6,544,000Source | 5,490,000Source | 7,497,000Source | 25,262,000Source | 21,230,000Source | 13,173,000Source | 4,025,000Source |
| Operating ExpensesUSD | — | — | 100,747,000Source | 59,884,000Source | — | 87,954,000Source | — | 78,808,000Source | 371,113,000Source | 247,078,000Source | 165,804,000Source | 139,865,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 2,000,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 24,721,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 10,000,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 20,750,000Source | — | 20,874,000Source | 15,288,000Source | 18,265,000Source | 14,108,000Source | 67,482,000Source | 53,883,000Source | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | — | — | 31,750,000Source | 25,169,000Source | 31,555,000Source | 22,835,000Source | 119,982,000Source | — | — | — |
| Operating Income (Loss)USD | — | — | -79,997,000Source | -59,884,000Source | -73,010,000Source | -72,666,000Source | -78,815,000Source | -64,700,000Source | -303,631,000Source | -193,195,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -74,116,000Source | -54,404,000Source | -68,322,000Source | -66,122,000Source | -73,325,000Source | -57,203,000Source | -278,369,000Source | -171,965,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | 5,000Source | — | 8,000Source | 226,000Source | 297,000Source | 2,018,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -74,116,000Source | -54,404,000Source | -68,327,000Source | -66,122,000Source | -73,333,000Source | -57,429,000Source | -278,666,000Source | -173,983,000Source | -152,631,000Source | -135,840,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.85Source | -0.63Source | -0.77Source | -0.75Source | -0.83Source | -0.66Source | -3.18Source | -2.02Source | -2.08Source | -2.03Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.85Source | -0.63Source | -0.77Source | -0.75Source | -0.83Source | -0.66Source | -3.18Source | -2.02Source | -2.08Source | -2.03Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 87,645,000Source | 86,950,000Source | 88,855,000Source | 87,586,000Source | 88,610,000Source | 87,415,000Source | 87,676,000Source | 86,161,000Source | 73,229,000Source | 66,990,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 87,645,000Source | 86,950,000Source | 88,855,000Source | 87,586,000Source | 88,610,000Source | 87,415,000Source | 87,676,000Source | 86,161,000Source | 73,229,000Source | 66,990,000Source |
| Interest Expense (non-operating)USD | — | — | 393,000Source | 412,000Source | 345,000Source | 391,000Source | 336,000Source | 382,000Source | 1,512,000Source | 1,619,000Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 32,839,000Source | 18,179,000Source | — | 25,169,000Source | — | 22,835,000Source | — | 77,111,000Source | 50,569,000Source | 47,053,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -278,369,000Source | — | — | — |
| Interest and Other IncomeUSD | — | — | 6,274,000Source | 5,892,000Source | 5,033,000Source | 6,935,000Source | 5,826,000Source | 7,879,000Source | 26,774,000Source | 22,849,000Source | 14,722,000Source | 4,254,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 1,549,000Source | 229,000Source |
| Nonoperating Income (Expense)USD | — | — | 5,881,000Source | 5,480,000Source | 4,688,000Source | 6,544,000Source | 5,490,000Source | 7,497,000Source | 25,262,000Source | 21,230,000Source | 13,173,000Source | 4,025,000Source |
| Operating ExpensesUSD | — | — | 100,747,000Source | 59,884,000Source | — | 87,954,000Source | — | 78,808,000Source | 371,113,000Source | 247,078,000Source | 165,804,000Source | 139,865,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 2,000,000Source |
| Research and Development ExpenseUSD | — | — | 67,908,000Source | 41,705,000Source | 61,891,000Source | 62,785,000Source | 65,263,000Source | 55,973,000Source | 251,074,000Source | 169,967,000Source | 115,235,000Source | 92,812,000Source |
| Cost of Revenue | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
| Costs and Expenses | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-299972
Filing attachments
d18057dex411.htm · S-3ASR · 2026-11-10
Exhibit 4.11 K URA O NCOLOGY, I NC. AND _____________, A S W ARRANT A GENT F ORM OF C OMMON S TOCK W ARRANT A GREEMENT D ATED A S O F __________ K URA O NCOLOGY, I NC. F ORM OF C OMMON S TOCK W ARRANT A GREEMENT T HIS C OMMON S TOCK W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between K URA O NCOLOGY, I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust …
Read attachment ↗d18057dex412.htm · S-3ASR · 2026-11-10
Exhibit 4.12 K URA O NCOLOGY, I NC. AND _____________, A S W ARRANT A GENT F ORM OF P REFERRED S TOCK W ARRANT A GREEMENT D ATED A S O F __________ K URA O NCOLOGY, I NC. F ORM OF P REFERRED S TOCK W ARRANT A GREEMENT T HIS P REFERRED S TOCK W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between K URA O NCOLOGY, I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corpora…
Read attachment ↗d18057dex413.htm · S-3ASR · 2026-11-10
Exhibit 4.13 K URA O NCOLOGY, I NC. AND _____________, A S W ARRANT A GENT F ORM OF D EBT S ECURITIES W ARRANT A GREEMENT D ATED A S O F __________ K URA O NCOLOGY, I NC. F ORM OF D EBT S ECURITIES W ARRANT A GREEMENT T HIS D EBT S ECURITIES W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between K URA O NCOLOGY, I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corpora…
Read attachment ↗d18057dex48.htm · S-3ASR · 2026-11-10
Exhibit 4.8 KURA ONCOLOGY, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20__ Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 …
Read attachment ↗kura-ex99_1.htm · 8-K · 2026-11-10
Exhibit 99.1 Kura Oncology Reports THIRD Quarter 2026 Financial Results AND CORPORATE UPDATE - KOMZIFTI®(ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% - - KOMZIFTI maintained majority share of new patient starts of the menin inhibitor class in the R/R NPM1-mutated AML market - - Eight abstracts accepted for ASH 2026, including two oral presentations on FLT3 inhibitor combinations, highlighting expandi…
Read attachment ↗kura-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 kura-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kura Oncology Reports SECOND Quarter 2026 Financial Results - KOMZIFTI®(ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q - - KOMZIFTI® achieved majority share of new patient starts in R/R NPM1-m AML menin inhibitor class, establishing leadership after just two full quarters of launch - - Long-term, frontline AML data presented at EHA 2026 support pote…
Read attachment ↗